Replies to post #152289 on Avid Bioservices Inc (CDMO)

[biopharm]

BioBS2012, thanks for the link and I happened to see the familiar name again of now President of MD Anderson = Ronald DePinho, MD. I first started looking into Ronald DePinho after writing this post here and trying to look for some links to Calico/MD Anderson..etc so I had to dig deeper after seeing this quote from your post below.

"Jim Allison richly deserves this wonderful prize for his pioneering research into how tumors evade destruction by immune system attack and how to overcome that defense by treating the immune system, rather than the cancer directly," said MD Anderson President Ronald DePinho, M.D. "I extend my deepest appreciation to the Breakthrough Prize selection committee and its visionary sponsors for their recognition of Jim's work that has offered real hope for cancer patients around the world."

-----------------------------------------------------------------

First, I am starting this off on the basis that "in general" scientific advisory boards for companies are there due to them agreeing with one another that a particular company is pursuing and since we have already seen Dr. Allison ( supporter of Yervoy = supporter of BMY ) .... so I try to look for some connections further ..

Also supporting the Company’s efforts is a Scientific Advisory Board featuring some of the most renowned scientific experts within the fields of oncology and metabolism including; Paul S. Anderson, Ph.D., Retired executive of Bristol-Myers Squibb and Merck ; Ronald A. DePinho, M.D., Dana-Farber Cancer Institute and Harvard Medical School; Pier Paolo Pandolfi, M.D., Ph.D., Beth Israel Deaconess Medical Center; Homer L. Pearce, Ph.D., retired executive of Eli Lilly & Company; David M. Sabatini, M.D., Ph.D., Whitehead Institute and the Massachusetts Institute of Technology; Bruce M. Spiegelman, Ph.D., Dana-Farber Cancer Institute and Harvard Medical School; and the Company’s founders, Cantley, Mak and Thompson.

http://www.agios.com/news-detail.php?id=24

-------------------------------------------------------------

Guess where Dr. Paul S. Anderson also serves as Scientific Advisor .... ? you have it, the company that Steve Worsley just left ... Centrose!

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94843797&txt2find=centrose|steve|worsley

------------------------------------------------------------

Dr. Paul S. Anderson, Ph.D., serves as Scientific Advisor of Centrose LLC.

http://investing.businessweek.com/research/stocks/people/person.asp?personId=626322&ticker=VRTX&previousCapId=31498&previousTitle=IRONWOOD%20PHARMACEUTICALS%20INC

http://centrosepharma.com/about-centrose/board-of-advisors/

-----------------------------------------------------------

Now... I like to connect the dots and try to observe how all is falling into place, but I have to ask myself: IF Peregrine just added some key scientific advisors and they were strategically chosen ........ I ask myself they leave out Paul S. Anderson (ex BMS Executive) and possibly he was too close to BMS as a former Executive? and they bring on someone who battled in the trenches so to speak at the conference table on partnering/licensing deals and many are not looking forward to seeing him back at the table with Bavituximab's MOA and cumulative clinical data by his side.

Who knows?.... but all I do know is Peregrine is showcasing their #1 drug in Bavituximab against BMS's #1 FDA approved drug in Yervoy and I say there is no competition. Bavituximab wins with one hand or arm : ) tied behind its back... oh, they did have one arm tied behind its back for that 60% as a matter of fact. If BMS wants a fair fight.... Bavi just may show 109%+ numbers and 200-300% better response rates in combination matches!